Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Alcohol misuse and smoking constitute two of the three leading preventable causes of death in the United States. The purpose of this research study is to develop an intervention designed to help people stop drinking alcohol and stop smoking at the same time.
Alcohol misuse and smoking constitute two of the three leading preventable causes of death in the United States. Reluctance to treat tobacco dependence among those with AUD is misguided as recent research suggests smoking cessation treatment can be effective, does not increase risk of relapse to alcohol, and may even improve rates of sobriety. There is strong evidence for the short-term efficacy for alcohol misuse and smoking of contingency management (CM). It is an intensive behavioral therapy that provides incentives (vouchers, money) to individuals misusing substances contingent upon objective evidence from drug use. Implementation of CM has been limited because of the need to verify abstinence multiple times daily using clinic based monitoring. The investigators recently developed a smart-phone application which allows a patient to video themselves several times daily while using a small CO monitor and to transmit the data to a secure server which has made the use of CM for outpatient smoking cessation portable and feasible. This mobile CM (mCM) approach paired with cognitive-behavioral counseling and pharmacological smoking cessation aids has been effective in reducing smoking.
Thus, the purpose of this project is to develop a combined alcohol and smoking mCM intervention. The intervention will be developed in two successive cohorts of five participants, who will provide information on treatment acceptability and feasibility. A third cohort of participants (n=45) will participate in a randomized clinical trials to further examine feasibility and efficacy. The long term goal is to develop mCM procedures that will be used as part of a multi-component intervention to concurrently and effectively treat both alcohol misuse and smoking. As part of this project, the investigators will develop a multi-component telehealth alcohol and smoking mCM intervention. It will include mCM, cognitive-behavioral phone counseling, and standard smoking cessation pharmacotherapy. The work proposed in these aims will provide the first step toward implementation of an innovative approach that builds upon the power of mHealth technology to reduce the prevalence of both alcohol misuse and smoking.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Experimental | This arm includes a proactive tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, a tele-medicine clinic for access to smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM). |
|
| Tele-health for Alcohol and Smoking Cessation | Active Comparator | This arm includes a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and tele-medicine clinic for access to smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants will receive monetary compensation for each assessment, regardless of abstinence. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nicotine Replacement Therapy | Other | Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Who Self-report Prolonged Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | 6 month follow-up |
| Number of Participants Whose Prolonged Abstinence From Smoking is Bio-verified | Self-reported prolonged abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence. | 6 month follow-up |
| Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | Participants will be asked to report on alcohol use since two weeks past quit date | 6 month follow-up |
| Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence. | 6 month follow-up |
| Number of Participants Who Self-report Prolonged Dual Abstinence From Both Smoking and Alcohol | Participants will be asked to report on smoking and alcohol use since two weeks past quit date | 6 month follow-up |
| Number of Participants Whose Prolonged Dual Abstinence From Alcohol and Smoking is Bio-verified | Self-reported prolonged abstinence from smoking will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | 7-day point prevalence abstinence is defined as no smoking in the prior 7 days. | 6 month follow-up |
| Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eric A. Dedert, Ph.D. | Study Principal Investigator | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27706 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Tele-health Mobile Contingency Management Intervention | This arm includes a tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM). Nicotine Replacement Therapy: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings Bupropion: All medically eligible participants will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up. Cognitive Behavioral Treatment: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation. Mobile Contingency Management: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence. |
| FG001 | Tele-health for Alcohol and Smoking Cessation | This arm includes a tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants receive monetary compensation for each assessment, regardless of abstinence. Nicotine Replacement Therapy: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings Bupropion: medically eligible participants will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up. Cognitive Behavioral Treatment: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation. Mobile Monitoring: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Tele-health Mobile Contingency Management Intervention | This arm includes a tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM). Nicotine Replacement Therapy: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings Bupropion: All medically eligible participants will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up. Cognitive Behavioral Treatment: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation. Mobile Contingency Management: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Who Self-report Prolonged Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | Posted | Count of Participants | Participants | 6 month follow-up |
|
Adverse events were collected for approximately seven months, from informed consent signature to the 6-month follow-up visit, which occurred six months after the substance quit date (session 4).
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Tele-health Mobile Contingency Management Intervention | This arm includes a tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM). Nicotine Replacement Therapy: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings Bupropion: All medically eligible participants will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up. Cognitive Behavioral Treatment: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation. Mobile Contingency Management: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hospitalization secondary to burned esophagus | Gastrointestinal disorders | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea/diarrhea | Gastrointestinal disorders | Non-systematic Assessment | Participants reported nausea or diarrhea as a possible side effect of bupropion |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Angela Kirby, MS | Duke University Medical Center | (919) 824-7729 | angela.kirby@duke.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 18, 2019 | Feb 1, 2021 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Sep 11, 2018 | Mar 25, 2021 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D016540 | Smoking Cessation |
| D000428 | Alcohol Drinking |
| ID | Term |
|---|---|
| D015438 | Health Behavior |
| D001519 | Behavior |
| D004327 | Drinking Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000095488 | Nicotine Replacement Therapy |
| D000074164 | Nicotine Chewing Gum |
| D057968 | Transdermal Patch |
| D009330 | Nebulizers and Vaporizers |
| D016642 | Bupropion |
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
| D002638 | Chewing Gum |
| D053149 | Plant Gums |
| D001704 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Bupropion | Drug | All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up. |
|
|
| Cognitive Behavioral Treatment | Behavioral | Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation. |
|
|
| Mobile Contingency Management | Behavioral | Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence. |
|
|
| Mobile Monitoring | Behavioral | Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence. |
|
| 6 month follow-up |
30-day point prevalence abstinence is defined as no smoking in the prior 30 days |
| 6 month follow-up |
| Change in the Proportion of Days in Which Consumed Alcohol Compared to Pre-quit Use | Participants will self-report number of days drank alcohol in the past 30 days and this will be compared to self-reported number of days drank alcohol in 30 days prior to quit. | 6 month follow-up |
| Change in the Number of Standard Alcoholic Beverages Consumed Per Week Compared to Pre-quit Use | Participants will self-report number of alcoholic beverages consumed in past 7 days and this will be compared to self-reported number of alcoholic beverages consumed in 7 days prior to quit. | 6 month follow-up |
| Change in the Number of Heavy Drinking Episodes Compared to Pre-quit Use | Participants will self-report number of heavy drinking episodes in the past 30 days and this will be compared to self-reported number of heavy drinking episodes in 30 days prior to quit. | 6 month follow-up |
| Number of Participants Who Are Able to Achieve Recommended Drinking Limits (i.e., Less Than or Equal to 14 Drinks Per Week and Fewer Than 5 Drinks Per Day for Men; Less Than or Equal to 7 Days Per Week and Less Than 4 Drinks Per Day for Women) | Participants will be asked to report on alcohol use in past week | 6 month follow-up |
| Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | Participants will be asked to report on alcohol use since two weeks past quit date | 6 week follow-up (i.e., end of treatment visit) |
| Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence. | 6 week follow-up (i.e., end of treatment visit) |
| Change in Number of Average Cigarettes Smoked Per Day | Participants will self-report average number of cigarettes smoked in the past week and this will be compared to self-reported number of smoked in the week prior to quit. | 6 month follow-up |
| Change in the Proportion of Days in Which Smoked Compared to Pre-quit Use | Participants will self-report number of days smoked in the past 30 days and this will be compared to self-reported number of days smoked 30 days prior to quit. | 6 month follow-up |
| Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | 6 week follow-up (i.e., end of treatment visit) |
| Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
| Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | Participants will be asked to report on alcohol use since two weeks past quit | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
| Number of Participants Who Self-report Prolonged Abstinence From Smoking | Participants will be asked to report on alcohol use since two weeks past quit | 6 week follow-up (i.e., end of treatment visit) |
| Number of Participants Who Self-report Prolonged Abstinence From Smoking | Participants will be asked to report on alcohol use since two weeks past quit | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
| Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | 6 week follow-up (i.e., end of treatment visit) |
| Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
| Number of Smoking Quit Attempts | Participants will be asked to report the number of quit attempts made since quit date | 6 week follow-up (i.e., end of treatment visit) |
| Number of Smoking Quit Attempts | Participants will be asked to report the number of quit attempts made since quit date | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
| Number of Smoking Quit Attempts | Participants will be asked to report the number of quit attempts made since quit date | 6-month follow-up |
| BG001 | Tele-health for Alcohol and Smoking Cessation | This arm includes a tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants receive monetary compensation for each assessment, regardless of abstinence. Nicotine Replacement Therapy: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings Bupropion: medically eligible participants will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up. Cognitive Behavioral Treatment: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation. Mobile Monitoring: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| OG001 | Tele-health for Alcohol and Smoking Cessation | This arm includes a tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants receive monetary compensation for each assessment, regardless of abstinence. Nicotine Replacement Therapy: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings Bupropion: medically eligible participants will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up. Cognitive Behavioral Treatment: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation. Mobile Monitoring: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence. |
|
|
| Primary | Number of Participants Whose Prolonged Abstinence From Smoking is Bio-verified | Self-reported prolonged abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence. | Posted | Count of Participants | Participants | 6 month follow-up |
|
|
|
| Primary | Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | Participants will be asked to report on alcohol use since two weeks past quit date | Posted | Count of Participants | Participants | 6 month follow-up |
|
|
|
| Primary | Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence. | This subset of participants self-reported prolonged abstinence from alcohol. | Posted | Count of Participants | Participants | 6 month follow-up |
|
|
|
| Primary | Number of Participants Who Self-report Prolonged Dual Abstinence From Both Smoking and Alcohol | Participants will be asked to report on smoking and alcohol use since two weeks past quit date | Posted | Count of Participants | Participants | 6 month follow-up |
|
|
|
| Primary | Number of Participants Whose Prolonged Dual Abstinence From Alcohol and Smoking is Bio-verified | Self-reported prolonged abstinence from smoking will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence. | This subset of participants self-reported dual abstinence from alcohol use and smoking. | Posted | Count of Participants | Participants | 6 month follow-up |
|
|
|
| Secondary | Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | 7-day point prevalence abstinence is defined as no smoking in the prior 7 days. | Posted | Count of Participants | Participants | 6 month follow-up |
|
|
|
| Secondary | Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking | 30-day point prevalence abstinence is defined as no smoking in the prior 30 days | Posted | Count of Participants | Participants | 6 month follow-up |
|
|
|
| Secondary | Change in the Proportion of Days in Which Consumed Alcohol Compared to Pre-quit Use | Participants will self-report number of days drank alcohol in the past 30 days and this will be compared to self-reported number of days drank alcohol in 30 days prior to quit. | Posted | Mean | Standard Deviation | drinking days per month | 6 month follow-up |
|
|
|
| Secondary | Change in the Number of Standard Alcoholic Beverages Consumed Per Week Compared to Pre-quit Use | Participants will self-report number of alcoholic beverages consumed in past 7 days and this will be compared to self-reported number of alcoholic beverages consumed in 7 days prior to quit. | Posted | Mean | Standard Deviation | drinks per week | 6 month follow-up |
|
|
|
| Secondary | Change in the Number of Heavy Drinking Episodes Compared to Pre-quit Use | Participants will self-report number of heavy drinking episodes in the past 30 days and this will be compared to self-reported number of heavy drinking episodes in 30 days prior to quit. | Posted | Mean | Standard Deviation | heavy drinking episodes | 6 month follow-up |
|
|
|
| Secondary | Number of Participants Who Are Able to Achieve Recommended Drinking Limits (i.e., Less Than or Equal to 14 Drinks Per Week and Fewer Than 5 Drinks Per Day for Men; Less Than or Equal to 7 Days Per Week and Less Than 4 Drinks Per Day for Women) | Participants will be asked to report on alcohol use in past week | Posted | Count of Participants | Participants | 6 month follow-up |
|
|
|
| Secondary | Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | Participants will be asked to report on alcohol use since two weeks past quit date | Posted | Count of Participants | Participants | 6 week follow-up (i.e., end of treatment visit) |
|
|
|
| Secondary | Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence. | Posted | Count of Participants | Participants | 6 week follow-up (i.e., end of treatment visit) |
|
|
|
| Secondary | Change in Number of Average Cigarettes Smoked Per Day | Participants will self-report average number of cigarettes smoked in the past week and this will be compared to self-reported number of smoked in the week prior to quit. | Posted | Mean | Standard Deviation | cigarettes per day | 6 month follow-up |
|
|
|
| Secondary | Change in the Proportion of Days in Which Smoked Compared to Pre-quit Use | Participants will self-report number of days smoked in the past 30 days and this will be compared to self-reported number of days smoked 30 days prior to quit. | Posted | Mean | Standard Deviation | days | 6 month follow-up |
|
|
|
| Secondary | Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | Posted | Count of Participants | Participants | 6 week follow-up (i.e., end of treatment visit) |
|
|
|
| Secondary | Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | Posted | Count of Participants | Participants | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
|
|
|
| Secondary | Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | Participants will be asked to report on alcohol use since two weeks past quit | Posted | Count of Participants | Participants | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
|
|
|
| Secondary | Number of Participants Who Self-report Prolonged Abstinence From Smoking | Participants will be asked to report on alcohol use since two weeks past quit | Posted | Count of Participants | Participants | 6 week follow-up (i.e., end of treatment visit) |
|
|
|
| Secondary | Number of Participants Who Self-report Prolonged Abstinence From Smoking | Participants will be asked to report on alcohol use since two weeks past quit | Posted | Count of Participants | Participants | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
|
|
|
| Secondary | Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | Posted | Count of Participants | Participants | 6 week follow-up (i.e., end of treatment visit) |
|
|
|
| Secondary | Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking | Participants will be asked to report on smoking since two weeks past quit date | Posted | Count of Participants | Participants | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
|
|
|
| Secondary | Number of Smoking Quit Attempts | Participants will be asked to report the number of quit attempts made since quit date | Posted | Mean | Standard Deviation | smoking quit attempts | 6 week follow-up (i.e., end of treatment visit) |
|
|
|
| Secondary | Number of Smoking Quit Attempts | Participants will be asked to report the number of quit attempts made since quit date | Posted | Mean | Standard Deviation | smoking quit attempts | 8 week follow-up (i.e., Session 7, end of monitoring visit) |
|
|
|
| Secondary | Number of Smoking Quit Attempts | Participants will be asked to report the number of quit attempts made since quit date | Posted | Mean | Standard Deviation | smoking quit attempts | 6-month follow-up |
|
|
|
| 0 |
| 30 |
| 2 |
| 30 |
| 6 |
| 30 |
| EG001 | Tele-health for Alcohol and Smoking Cessation | This arm includes a tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants receive monetary compensation for each assessment, regardless of abstinence. Nicotine Replacement Therapy: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings Bupropion: medically eligible participants will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up. Cognitive Behavioral Treatment: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation. Mobile Monitoring: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence. | 0 | 15 | 0 | 15 | 0 | 15 |
| Hospitalization secondary to flu | General disorders | Non-systematic Assessment |
|
|
| Increased stress | Psychiatric disorders | Non-systematic Assessment |
|
| Threat of domestic violence | Psychiatric disorders | Non-systematic Assessment | Participant left home to avoid domestic violence. |
|
| Dental surgery | Surgical and medical procedures | Non-systematic Assessment |
|
| Increase in depressed mood | Psychiatric disorders | Non-systematic Assessment |
|
| Skin irritation | Skin and subcutaneous tissue disorders | Non-systematic Assessment | Participant reported skin irritation at nicotine patch placement site. |
|
Not provided
Not provided
| Biopolymers |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
| D061485 | Tobacco Use Cessation Devices |
| D002182 | Candy |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
| D004864 | Equipment and Supplies |
| D011427 | Propiophenones |
| D007659 | Ketones |
| D009930 | Organic Chemicals |